Taking people in SwedenNo phase
Studying why some heart failure patients respond better to treatment
Observational study collecting samples from adults with heart failure to find biomarkers.
Key facts
- Who runs it
- Karolinska University Hospital
- Where
- Stockholm, SwedenSee the site
- Trial code
- Registry title
- Responders and Non-responders in the Management of Heart Failure - Significance of Genetic Influence and Identification of Novel Informative Biomarkers
- Status
- Recruiting
- People taking part
- 5,000 people, planned
- Started
- 17 Feb 2021
- Expected to end
- 31 Dec 2030
- Type of study
- Observational
- Record updated
- 10 August 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with heart failure who are registered in the Swedish heart failure registry SwedeHF and give written consent.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Heart failure with symptoms and signs of heart failure, as judged by the local investigator.
Main reasons for not taking part
- Plasma donation within 1 month before joining
- Blood donation or blood loss of more than 500 mL in the 3 months before joining
- Previous bone marrow transplant from another person
- A condition that could put the patient at risk or affect the results, in the investigator's opinion
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Written informed consent
- Heart failure defined by symptoms and signs of heart failure as judged by the local investigator
- Registered in SwedeHF
Who cannot take part
- Plasma donation within 1 month of enrolment or any blood donation/blood loss >500 mL during the 3 months prior to enrolment
- Previous allogeneic bone marrow transplant (genetics)
- In the opinion of the investigator, condition/s that may either put the patient at risk on participation or influence the results or the patient's ability to participate in the study
Where in Sweden
- Karolinska University HospitalStockholm, SwedenContact: Camilla Hage, Ass profTaking people
About the trial
What the trial wants to find out
A biobank within the Swedish national heart failure quality registry SwedeHF.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Responders and Non-responders in the Management of Heart Failure - Significance of Genetic Influence and Identification of Novel Informative Biomarkers
- Plain-language title
- Studying why some heart failure patients respond better to treatmentGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Publications
- Record updated
- 10 August 2026